

Customizable OpenGUS immunoassay: a homogeneous detection system using split β -glucuronidase and label-free antibody

Bo Zhu^{1,‡}, Yukihiro Yamasaki^{2,‡}, Takanobu Yasuda¹, Cheng Qian³, Zhirou Qiu³,
Hiroshi Ueda^{1,†}, Tetsuya Kitaguchi^{1,*}

¹ Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan

² BioDynamics Laboratory Inc., Tokyo, Japan

³ Graduate School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan

‡ Equal contributions

† Deceased

*Correspondence:

Tetsuya Kitaguchi

kitaguc.t.aa@m.titech.ac.jp

Keywords: immunoassay, β -glucuronidase, antibody, Cry j 1, C-creative protein, lactoferrin, homogeneous

1 **Abstract**

2 We developed a customizable OpenGUS immunoassay for rapid and sensitive detection of
3 analytes, eliminating the need for any antibody modifications. This assay employs a label-free
4 whole antibody(ies), an antibody-binding domain derived from *Staphylococcal* protein A, and a
5 split β -glucuronidase (GUS) mutant, allowing for the replacement of antibodies to establish an
6 immunoassay for various targeted antigens. The working principle is that OpenGUS probe, the
7 fusion protein of antibody-binding protein and split GUS mutant, converts the antibody-antigen
8 interaction into GUS activation in a one-pot reaction. The split GUS mutant with decreased
9 background activation was generated by screening several mutations at a diagonal interface residue
10 H514. We optimized reaction buffer compositions, including organic solvent addition, salt
11 concentrations, and surfactant concentrations, to enhance the signal/background ratio of the assay.
12 In the optimal condition, we successfully customized OpenGUS fluorogenic immunoassays for
13 Japanese cedar pollen allergen Cry j 1, human C-creative protein, and human lactoferrin with over
14 10–20-fold maximum fluorescence responses with picomolar to low nanomolar level detection
15 limit within 15 min reaction time, by simply using commercially available IgGs. Moreover, in the
16 absence of a fluorometer such as outdoors or at home, analytes can be detected using a simple
17 smartphone or even the naked eye, with a pen-type UV-LED as the light source. We believe that
18 the customizable OpenGUS immunoassay will pave new ways for the prompt development of
19 rapid and sensitive homogeneous immunoassays for point-of-care diagnostics, high-throughput
20 testing, and on-site environmental assessment applications.

21 **Introduction**

22 Immunoassays have been instrumental in advancing scientific research [1,2], clinical diagnostics
23 [3,4], food safety control [5,6], and environmental monitoring [7] for several decades. These
24 assays leverage the specific binding properties of antibodies to detect and quantify target analytes,
25 which could range from small molecules to large proteins. From the very first radioimmunoassay
26 (RIA) [8] to the classic enzyme-linked immunosorbent assay (ELISA) [9], the multiple binding
27 and separation steps are included in these heterogeneous immunoassays. While they have
28 demonstrated reliability and robustness, their intricate multi-step procedures can cause long
29 operations and extra equipment requirements. An immunochromatography or lateral flow assay
30 (LFA) utilizes a paper device to simplify the separation and washing steps in a heterogeneous
31 immunoassay to achieve the analyte detection in a shorter period (5–30 min), but usually only
32 provides qualitative or semi-quantitative results [10,11].

33 In contrast, homogeneous immunoassays are capturing increasing attention in both research and
34 diagnostic fields [12,13]. The key advantage of these assays is the elimination of the separation or
35 washing steps, rendering the process more streamlined and less time-consuming. This simplicity
36 makes them particularly appealing for point-of-care testing and high-throughput scenarios [4,14].
37 The resonance energy transfer-based homogeneous immunoassays use two modified antibodies
38 (or antigen for competitive assay) with combinations of chemiluminescent dye [15], fluorescent
39 dye [16,17], fluorescent protein [18], and/or luciferase [18,19]. The analyte binding will trigger
40 the distance change between the donor and receptor of the resonance energy transfer pair, thus
41 changing the ratiometric signal. These resonance energy transfer-based assays did not adopt signal
42 amplification mechanisms, which can lead to a moderate response in practical usage. Recently, a
43 homogeneous immunoassay RAPPID used a robust split NanoLuc-modified antibodies to reach

44 over 5–30-fold ratiometric response against different analytes including protein biomarkers and
45 virus antigen, and the bioluminescence signal can be detected by digital camera benefiting from
46 the bright NanoLuc [14]. Previously, we reported several homogeneous immunoassays using
47 fusion proteins of antibody fragments and split *E. coli* β -glucuronidase (GUS) for small molecule
48 detection with enzyme-based signal amplification (OpenGUS antibody fragments) [20-22].
49 However, all the homogeneous immunoassays described above need antibody engineering or
50 modification procedures (most also need purification steps), which made the customization of the
51 assay and the screening of the optimal antibody difficult.




Fig. 1. Overview of OpenGUS immunoassay. (A) OpenGUS probe, a fusion protein of a split GUS mutant and two protein A-derived antibody-capturing Z domains (PZ) with fibronectin type III 7-8th domain (FN7-8) as a rigid spacer. (B) Scheme of OpenGUS homogeneous immunoassay by mixing OpenGUS probe, whole IgG antibody(ies), analyte, and substrate in one pot.

52 In this study, we developed a customizable OpenGUS immunoassay, for rapid and sensitive
53 detection of protein analytes without the need for antibody engineering or modifications. In this
54 immunoassay, an OpenGUS protein probe made of background-reduced split GUS and two protein

55 A-derived antibody-binding Z domains (PZ) (**Fig. 1A**), is used to convert the antibody-antigen
56 binding signal into a GUS reconstruction and activation, which effectively amplifies the signal by
57 producing fluorescent or colorimetric products in a short period. By simply mixing the antibodies
58 against targets of interest, OpenGUS probe, analytes, and substrate in one pot (**Fig. 1B**), we
59 successfully customized immunoassays for Japanese cedar pollen allergen Cry j 1, human C-
60 reative protein, and human lactoferrin, with picomolar to low nanomolar limit of detections (LOD)
61 and over 10–20-fold fluorescence responses within 15 min reaction time. Moreover, in the absence
62 of a fluorometer such as outdoors or at home, analytes can be detected using a simple smartphone
63 or even the naked eye, with a pen-type UV-LED as the light source. We believe that OpenGUS
64 immunoassay will pave new ways for the prompt development of rapid and sensitive homogeneous
65 immunoassays for point-of-care diagnostics, high-throughput testing, and on-site environmental
66 assessment applications.

67 **Results and Discussion**

68 **Preparation of split GUS and PZ fusion protein with different GUS H514 mutations**

69 The wild-type GUS is a homotetramer enzyme reporter in colorimetric and fluorogenic assays,
70 which can be engineered into split inactive homodimers by introducing interface mutants [22,23].
71 A thermostable split GUS mutant GUS_{IV5}-KW [21] was used in the bottom-up construction of the
72 OpenGUS probe prototype (**Fig. 1A**). The B domain of *staphylococcal* protein A-derived
73 antibody-binding protein, Z domain (PZ), has a specific binding affinity (10 nM) against the
74 fragment crystallizable (Fc) region of IgG1 antibodies [24,25], and also showed binding ability
75 against IgG2 and IgG4 [26]. Two PZ proteins were used in the OpenGUS probe to increase the
76 binding avidity to the two binding sites on the Fc region of an IgG antibody. A rigid linker protein,
77 7th and 8th domains of fibronectin type III, with 7 nm N–C terminal distance [27] was inserted

78 into the two PZ proteins to increase the searching efficiency of secondary binding site recognition.
79 To confirm the function of the designed probe prototype, the homogeneous detection for Japanese
80 cedar pollen allergen Cry j 1 was performed by using two mouse anti-Cry j 1 monoclonal IgG1
81 antibodies recognizing different epitopes (**Fig. 2A**). The fluorescence signal difference between
82 the reactions with and without analytes was not observed for this prototype. In the previous study,
83 introducing proper mutation at a diagonal interface residue H514 of GUS_{TR3337} reduced the
84 background signal of the split GUS_{TR3337} [22]. Therefore, we decided to investigate the effects of
85 the H514 mutants of GUS_{IV5-KW} on the OpenGUS immunoassay.

86 A positive charge mutant H514K (**Fig. 2B**), three small side chain mutants (**Fig. 2C-E**), a
87 conformational freedom reduced mutant H514P (**Fig. 3F**), and a negative charge mutant H514D
88 (**Fig. 2G**) were prepared (**Fig. S1**) and tested in the OpenGUS assay for Cry j 1 detection. Except
89 for the H514D mutant, all the other variants gave responses to the addition of Cry j 1 (**Fig. 2H-I**),
90 which demonstrated the feasibility of the OpenGUS immunoassay design. The H514K, H514A,
91 and H514S variants showed unreduced reaction rates and higher signal-background (S-B) after
92 analyte-triggered reconstruction (**Fig. 2H**). Among the above three mutants, only the H514A
93 variant showed stable or increased signal/background (S/B) during the signal development reaction
94 (**Fig. 2I**). These results demonstrated again the importance of H514 mutations for modulation of
95 the tetramerization functions of GUS. Therefore, we continued with the OpenGUS probe carrying
96 GUS_{IV5-KW-H514A} mutant in the following development of the assay.




Fig. 2. Effect of the GUS_{IV5}-KW interface mutations on OpenGUS immunoassay for Cry j 1 allergen detection. (A)-(G) Assays with the OpenGUS probe carrying different GUS_{IV5}-KW H514 mutants. (H) Signal-background plot of assays with different GUS mutants. (I) Signal/background plot of assays with different GUS mutants. F.I., fluorescence intensity; Ab, antibody; Ag, antigen; Cry j 1 concentration: 30 nM; n = 3; Data were expressed as mean ± standard deviation.

97 Improving the signal/background ratio by including organic solvent in OpenGUS reaction

98 Some organic solvents in aqueous solution can stabilize the protein [28]. The split GUS has
 99 the exposed hydrophobic residues which could be stabilized by a small amount of organic solvent
 100 thus reducing the autonomous reconstruction background. Three well-used solvents for dissolving
 101 substrate in enzymatic reactions including dimethyl sulfoxide (DMSO), ethanol, and N,N-
 102 dimethylformamide (DMF) were tested for background reducing effect (**Fig. 3A-C**). The addition
 103 of 6% DMSO significantly reduced the background while not interfering with signal development

104 after the addition of the Cry j 1 (**Fig. 3D-E**), which resulted in an improved S/B ratio. This
 105 interesting phenomenon could be related to the reported protein stabilization function of DMSO
 106 at lower concentrations (<10–20%) through the preferential hydration effect [29]. But, to minimize
 107 the potential denaturation effect of the DMSO on antibody and analyte, the DMSO will be included
 108 in the substrate solution in the following experiment as the last reagent to be added into the
 109 OpenGUS immunoassay before the signal measurement.




Fig. 3. Effect of the organic solvents in OpenGUS immunoassay for Cry j 1 allergen. (A) Assays in the presence of 6% (v/v) DMSO. (B) Assays in the presence of 6% (v/v) ethanol (EtOH). (C) Assays in the presence of 6% (v/v) DMF. (D) Signal-background plot of assays in the presence of different organic solvents. (E) Signal/background plot assays in the presence of different organic solvents. F.I., fluorescence intensity; Cry j 1 concentration: 30 nM; n = 3; Data were expressed as mean \pm standard deviation.

110 Revisit the reaction buffer composition for OpenGUS immunoassay

111 Based on the successful S/B ratio improvement using DMSO, the concentrations of two
 112 components in the reaction buffer, NaCl and Tween 20, were also optimized. The physiological
 113 salt concentration is not always the best for protein stabilization and functionalization [30].
 114 Therefore, no additional NaCl, 0.3 \times , 1 \times , and 3 \times physiological NaCl concentrations in reaction

115 buffers were investigated. Notably, the buffer without the addition of NaCl significantly increased
 116 both S-B and S/B for Cry j 1 detection (**Fig. 4A-B**). The concentrations of surfactant Tween 20
 117 (0–1%, v/v) were also tested, and the decreases of both S-B and S/B were observed if the Tween
 118 20 was not included in the reaction (**Fig. 4C-D**). And 0.1% or 0.5% Tween 20 was considered the
 119 optimal concentration for the OpenGUS immunoassay.




Fig. 4. Optimization of reaction buffer of OpenGUS immunoassay for Cry j 1 allergen detection. (A) Effect of NaCl concentration on the signal-background. (B) Effect of NaCl concentration on the signal/background. (C) Effect of Tween 20 concentration on the signal-background. (D) Effect of Tween 20 concentration on the signal/background. Bar graph in orange represents the sample used for normalization. PB: phosphate buffer without addition of NaCl; Cry j 1 concentration: 30 nM; Reaction time after adding fluorogenic substrate: 15 min; n = 3; Data were expressed as mean ± standard deviation.

120 **Pre-incubation is not essential for OpenGUS immunoassay**

121 In the above investigations, the OpenGUS probe, antibodies, and analytes were incubated at 4 °C
 122 for one hour before adding the substrate to maximize the antibody-antigen binding and split GUS

123 reconstruction. However, the long pre-incubation under temperature control is not ideal for point-
124 of-care testing applications. Therefore, we compared different temperatures and lengths of pre-
125 incubation to further simplify the assay using the OpenGUS probe. Firstly, the one-hour pre-
126 incubation at 4 °C and room temperature (25 °C) were compared, and the room temperature did
127 not reduce the S-B and S/B for Cry j 1 detection (**Fig. 5A-B**). Next, the incubation was shortened
128 to 30 min or eliminated, and even though the S-B was reduced slightly, the S/B did not become
129 worse when no pre-incubation was performed (**Fig. 5C-D**). These results indicated that pre-
130 incubation is not an essential step in OpenGUS immunoassay for sufficient analyte detection.




Fig. 5. Preincubation conditions optimization of OpenGUS immunoassay for Cry j 1 allergen detection. (A) Effect of preincubation temperature on the signal-background. (B) Effect of preincubation temperature on the signal/background. (C) Effect of preincubation length on the signal-background. (D) Effect of preincubation length on the signal/background. Bar graph in orange represents the sample used for normalization. Cry j 1 concentration: 30 nM; Reaction time after adding fluorogenic substrate: 15 min; n = 3; Data were expressed as mean \pm standard deviation.

131 **OpenGUS immunoassays for various protein analytes**




Fig. 6. OpenGUS immunoassays for detection of various protein analytes. (A) Dose-response curve for Cry j 1 detection with two antibodies. (B) Dose-response curve for human C-reactive protein (hCRP) detection with a single antibody, pentamer molar concentration. (C) Dose-response curve for human lactoferrin (hLF) detection with a single antibody, monomer molar concentration. Reaction time after adding fluorogenic substrate: 15 min; $n = 3$; Data were expressed as mean \pm standard deviation. Pictures of the reaction wells taken using a smartphone were displayed above the data points in the dose-response curves.

132 The dose-response curve for pollen allergen Cry j 1 detection using OpenGUS immunoassay
 133 was measured under the optimized reaction condition without pre-incubation. After 15 min
 134 reaction, the LOD was determined as 1.4 nM, and the S/B response to 30 nM Cry j 1 was 12-fold
 135 (**Fig. 6A**). When using a pen-type UV-LED to irradiate the reaction wells, the blue color changes
 136 can be observed using a simple smartphone or even the naked eye, which makes the rapid analyte
 137 detection with OpenGUS immunoassay can be achieved in the absence of a fluorometer, e.g., harsh
 138 fieldwork environment, home, or basic laboratories in developing countries. The Cry j 1 detection

139 within a shorter reaction time is also possible, with a slight trade-off in the S/B and LOD. For
140 example, in a 5-minute reaction, the LOD was 3.4 nM, and the fluorescence response to 30 nM
141 Cry j 1 was 5-fold (**Fig. S2A**). The colorimetric readout using p-nitrophenyl β -D-glucuronide
142 (PNPG) as substrate was also demonstrated for Cry j 1 detection. With a pre-incubation of 30
143 minutes, the assay detected the analyte with a LOD of 0.86 nM after a 30-minute reaction (**Fig.**
144 **S3**). Since the condition optimization in this study was focused on the fluorogenic assay, further
145 optimization for the colorimetric assay, including the pre-incubation and reaction time, could be
146 done for the customized colorimetric assays if necessary.

147 Next, we customized the OpenGUS immunoassay to detect human C-reactive protein (hCRP,
148 homopentamer, 114 kDa), which is an inflammation and cardiovascular disease biomarker [31].
149 The hCRP serum level in healthy adults is less than 0.3 mg/dL (260 nM), and can elevate to over
150 50 mg/dL (44 μ M) during acute infections. Because hCRP is a protein oligomer, we were able to
151 use single mouse monoclonal anti-hCRP IgG1 antibody instead of an antibody pair to trigger the
152 split GUS activation (**Fig. 6B**). After a 15-minute reaction, the LOD was determined as 0.17 nM,
153 and the response to 3 nM hCRP was 21-fold. The signal decrease was observed at a higher hCRP
154 concentration than 3 nM (a hook effect), which could be due to each antibody being occupied by
155 one or more antigens instead of the one antigen-two antibody complex, thus reducing the GUS
156 reconstruction [32]. The hCRP detection within 5 minutes was also possible with a similar LOD
157 of 0.13 nM. The fluorescence response to 3 nM hCRP was reduced to 8-fold (**Fig. S2B**) as expected.

158 We also customized OpenGUS immunoassay for the detection of human lactoferrin (hLF, mixed
159 multimer, monomer 82 kDa). It has important immunological properties, such as antibacterial and
160 antiviral functions (including SARS-CoV-2), and can act as biomarkers for various diseases [33].
161 The tear fluid hLF is a biomarker for ocular surface disease [34], and the saliva hLF could be used
162 as a non-invasive biomarker of cerebral vulnerability in the general aging population [35], and

163 periodontal disease [36]. One report suggested that the hLF could start forming tetramer from
164 around 10 pM and completely the oligomerization at around 1 nM concentration [37]. Therefore,
165 same as the hCRP, one mouse monoclonal anti-hLF IgG1 antibody was used to customize the
166 OpenGUS assay for hLF detection (**Fig. 6C**). The LOD was determined as 75 pM, and the response
167 to 10 nM hLF was 12-fold after a 15 min reaction. In the 5-minute detection test, the LOD was
168 determined as 130 pM, and the fluorescence response to 10 nM hLF was 5-fold (**Fig. S2C**). The
169 working range of this assay is several orders of magnitude lower than the normal physiological
170 concentration of hLF in tear fluid (~ 2 mg/mL, 24 μ M monomer) and saliva (~ 0.8 mg/dL, 0.1 μ M
171 monomer) [38,39].

172 **Conclusions**

173 In this research, we developed a customizable OpenGUS immunoassay, employing label-free
174 IgG antibodies together with a fusion protein probe of a low-background split GUS mutant and
175 antibody Fc region-binding proteins. Reaction conditions including organic solvent addition, NaCl
176 concentration, surfactant Tween 20 concentration, and the requirement of pre-incubation were
177 optimized and discussed to improve the S/B ratio and the simplicity of the assay procedure. We
178 demonstrated the detections of three protein analytes using commercially available IgG antibodies,
179 achieving LOD ranging from picomolar to low nanomolar levels within a 15-minute reaction
180 window. Notably, for oligomer analytes such as hCRP and hLF in this study, only a single antibody
181 is needed to customize an OpenGUS immunoassay. Additionally, in scenarios lacking a
182 fluorometer, like outdoor settings, homes, or less-equipped labs, the assay outcomes can be
183 discerned using a smartphone or even the naked eye when using a pen-type UV-LED as the light
184 source. Given its ease of customization, rapid and sensitive detection capabilities, and versatile
185 readout options, we believe that OpenGUS immunoassay will pave new ways for the prompt

186 development of homogeneous immunoassays for point-of-care diagnostics, high-throughput
187 testing, and on-site environmental assessment applications.

188 **Materials and Methods**

189 **Materials**

190 *E. coli* SHuffle[®] T7 Express lysY was purchased from New England Biolabs, USA. B-PER[™]
191 Bacterial Protein Extraction Reagent was purchased from Thermo Fisher Scientific, USA.
192 TALON[®] Metal Affinity Resin was purchased from Takara Bio, Japan. Mouse anti-Cry j 1
193 monoclonal antibodies (clones 053 and 013) and Cry j 1 protein (catalog no. HBL-C-1) were
194 obtained from BioDynamics Laboratory, Japan. Mouse anti-human C-creative protein monoclonal
195 antibody (clone 160.10G10) and hCRP (catalog no. PHP277) were purchased from Bio-Rad
196 Laboratories, Japan. Mouse anti-human lactoferrin monoclonal antibody (clone 1A1) was
197 purchased from HyTest, Finland. Lactoferrin from human milk (catalog no. 7550-2) was purchased
198 from BioVision, USA. Colorimetric substrate p-nitrophenyl β -D-glucuronide (PNPG, catalog no.
199 N0618) was purchased from Tokyo Chemical Industry, Japan. Other chemicals were purchased
200 from FUJIFILM Wako Pure Chemicals, Japan unless otherwise indicated.

201 **Expression and purification of OpenGUS protein probe**

202 The synthesized whole OpenGUS probe sequences was cloned into pETIA vector
203 (BioDynamics Laboratory) between ATG start codon and TAA stop codon as expression plasmids.
204 The expression plasmid was transformed into *E. coli* SHuffle[®] T7 Express lysY competent cells.
205 Cells were grown in LB medium (Difco LB broth, Lennox, BD) containing 100 μ g/mL ampicillin
206 at 30 °C with shaking at the speed of 150 rpm to an OD₆₀₀~0.4–0.5, then the expression was
207 induced with 0.5 mM isopropyl β -D-thiogalactopyranoside (IPTG) for 16 h at 16 °C. The cells
208 were harvested by centrifugation at 4 °C. The pellet was lysed with B-PER[™] Bacterial Protein

209 Extraction Reagent. The lysate was recovered using centrifugation at $10,000 \times g$, for 25 min at
210 $4\text{ }^{\circ}\text{C}$, and the OpenGUS probe in the supernatant was purified with TALON[®] Metal Affinity Resin
211 according to the manual after resin equilibration with purification buffer (50 mM sodium
212 phosphate, 300 mM NaCl, pH 8.2). Proteins bound to the resin were eluted using elution buffer
213 (purification buffer with 500 mM imidazole), and were kept on ice for 1 h. Glycerol was added to
214 the eluted OpenGUS probe, to a final concentration of 25%, and the protein solution was stored at
215 $-80\text{ }^{\circ}\text{C}$. The purified proteins were analyzed using SDS-PAGE, and the concentration was
216 determined by the band intensity after Coomassie brilliant blue staining using bovine serum
217 albumin as standard on the same gel.

218 **OpenGUS homogeneous immunoassay**

219 A phosphate buffer (8.1 mM Na_2HPO_4 , 1.47 mM KH_2PO_4 , pH was adjusted to 7.4) is the base
220 of all the reaction buffers used in this study. The 0.5% (v/v) Tween 20 was included in the
221 optimized reaction buffer. The fluorogenic substrate 4-methylumbelliferyl β -D-glucuronide (4-
222 MUG) or colorimetric substrate PNPG was dissolved in the optimized reaction buffer containing
223 12% (v/v) DMSO at the concentration of 0.6 mg/mL as a substrate solution. The OpenGUS probe
224 (final conc. 7.5 nM), IgG antibody (final conc. 7.5 nM for each in an antibody pair or 15 nM for
225 single antibody), analyte, and substrate solution (final conc. 0.3 mg/mL) were mixed in above
226 order before the fluorescence intensity or absorbance measurement.

227 The fluorescence intensity was measured in a 96-well black microplate (catalog no. 675076,
228 Greiner Bio-One, Austria) using a microplate reader CLARIOstar (BMG Labtech, Germany) at
229 $25\text{ }^{\circ}\text{C}$ with excitation and emission wavelengths of 360/20 nm and 450/30 nm (center/bandwidth),
230 respectively. The pictures of the reaction wells were taken by a smartphone (G8441, SONY, Japan)
231 with fixed ISO (200), shutter speed (1/16 s), and aperture (f/2.0), using a pen-type UV-LED (PW-

232 UV141P-01, KONTEC, Japan) as an excitation light source (LED unit: peak wavelength 375 nm,
233 spectrum half-width 9 nm, radiant flux 1160 mW, part no. NVSU119C, NICHIA, Japan). In the
234 colorimetric assays, the absorbance at 405 and 660 nm was measured in a 96-well clear microplate
235 (catalog no. 3590, Corning, USA) using a microplate reader SH-1000 (Corona Electric, Japan).

236 **Dose-response curve fitting**

237 Dose-response curves were fitted to a four-parameter logistic equation (1) using SciDAVis
238 software (version 2.4.0). The limit of detection was calculated as the concentration corresponding
239 to the mean blank value plus three times its standard deviation.

$$240 \quad y = d + \frac{a-d}{1 + \left(\frac{x}{c}\right)^b} \quad (1)$$

241 **Author Contributions**

242 T.K. and H.U. conceived the study. B.Z. and Y.Y. designed and performed the experiments.
243 T.Y., C.Q., and Z.Q. supported performing the experiments. B.Z. wrote the original manuscript.
244 H.U. and T.K. provided the resources and supervised the study. All authors discussed the results
245 and edited the manuscript.

246 **Conflicts of Interest**

247 B.Z., T.Y., H.U., and T.K. received honoraria from HikariQ Health, Inc. for another unrelated
248 project.

249 **Acknowledgments**

250 We thank Toru Hisabori from the Tokyo Institute of Technology for critical discussion and
251 advice on this work. This work was supported in part by JSPS KAKENHI Grant Numbers
252 JP22H05176 (to T.K.) and JP21K14468 (to B.Z.) from the Japan Society for the Promotion of

253 Science, a Research Grant from the Nakatani Foundation (to H.U. and T.K.), and the Mishima
254 Kaiun Memorial Foundation (to T.K.).

255 **References**

256 [1] Boguszewska, K., Szewczuk, M., Urbaniak, S. and Karwowski, B.T. (2019). Review:
257 immunoassays in DNA damage and instability detection. *Cell Mol Life Sci* 76, 4689-4704.

258 [2] Dai, Y.C., Sato, Y., Zhu, B., Kitaguchi, T., Kimura, H., Ghadessy, F.J. and Ueda, H. (2022).
259 Intra Q-body: an antibody-based fluorogenic probe for intracellular proteins that allows live cell
260 imaging and sorting. *Chemical Science* 13, 9739-9748.

261 [3] Voller, A., Bidwell, D.E. and Bartlett, A. (1976). Enzyme immunoassays in diagnostic
262 medicine. Theory and practice. *Bull World Health Organ* 53, 55-65.

263 [4] Zhu, B. et al. (2022). Rapid and sensitive SARS-CoV-2 detection using a homogeneous
264 fluorescent immunosensor Quenchbody with crowding agents. *Analyst* 147, 4971-4979.

265 [5] Samarajeewa, U., Wei, C.I., Huang, T.S. and Marshall, M.R. (1991). Application of
266 immunoassay in the food industry. *Crit Rev Food Sci Nutr* 29, 403-434.

267 [6] Su, J. et al. (2022). The Patrol Yeast: A new biosensor armed with antibody-receptor
268 chimera detecting a range of toxic substances associated with food poisoning. *Biosens Bioelectron*
269 219, 114793.

270 [7] Ahn, K.C., Kim, H.J., McCoy, M.R., Gee, S.J. and Hammock, B.D. (2011). Immunoassays
271 and biosensors for monitoring environmental and human exposure to pyrethroid insecticides. *J*
272 *Agric Food Chem* 59, 2792-2802.

273 [8] Berson, S.A., Yalow, R.S., Bauman, A., Rothschild, M.A. and Newerly, K. (1956). Insulin-
274 I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation
275 of insulin treated subjects. *J Clin Invest* 35, 170-190.

- 276 [9] Engvall, E. and Perlmann, P. (1972). Enzyme-linked immunosorbent assay, Elisa. 3.
277 Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated
278 tubes. *J Immunol* 109, 129-135.
- 279 [10] Koczula, K.M. and Gallotta, A. (2016). Lateral flow assays. *Essays Biochem* 60, 111-120.
- 280 [11] Banerjee, R. and Jaiswal, A. (2018). Recent advances in nanoparticle-based lateral flow
281 immunoassay as a point-of-care diagnostic tool for infectious agents and diseases. *Analyst* 143,
282 1970-1996.
- 283 [12] Takkinen, K. and Zvirbliene, A. (2019). Recent advances in homogenous immunoassays
284 based on resonance energy transfer. *Curr Opin Biotechnol* 55, 16-22.
- 285 [13] Rani, A.Q., Zhu, B., Ueda, H. and Kitaguchi, T. (2023). Recent progress in homogeneous
286 immunosensors based on fluorescence or bioluminescence using antibody engineering. *Analyst*
287 148, 1422-1429.
- 288 [14] Ni, Y. et al. (2021). A plug-and-play platform of ratiometric bioluminescent sensors for
289 homogeneous immunoassays. *Nat Commun* 12, 4586.
- 290 [15] Akhavan-Tafti, H. et al. (2013). A homogeneous chemiluminescent immunoassay method.
291 *J Am Chem Soc* 135, 4191-4194.
- 292 [16] Ullman, E.F., Schwarzbarg, M. and Rubenstein, K.E. (1976). Fluorescent excitation
293 transfer immunoassay. A general method for determination of antigens. *J Biol Chem* 251, 4172-
294 4178.
- 295 [17] Ueda, H., Kubota, K., Wang, Y., Tsumoto, K., Mahoney, W., Kumagai, I. and Nagamune,
296 T. (1999). Homogeneous noncompetitive immunoassay based on the energy transfer between
297 fluorolabeled antibody variable domains (open sandwich fluoroimmunoassay). *Biotechniques* 27,
298 738-742.

299 [18] Arai, R., Nakagawa, H., Tsumoto, K., Mahoney, W., Kumagai, I., Ueda, H. and Nagamune,
300 T. (2001). Demonstration of a homogeneous noncompetitive immunoassay based on
301 bioluminescence resonance energy transfer. *Anal Biochem* 289, 77-81.

302 [19] Yu, X., Wen, K., Wang, Z., Zhang, X., Li, C., Zhang, S. and Shen, J. (2016). General
303 Bioluminescence Resonance Energy Transfer Homogeneous Immunoassay for Small Molecules
304 Based on Quantum Dots. *Anal Chem* 88, 3512-3520.

305 [20] Su, J., Dong, J.H., Kitaguchi, T., Ohmuro-Matsuyama, Y. and Ueda, H. (2018).
306 Noncompetitive homogeneous immunodetection of small molecules based on beta-glucuronidase
307 complementation (vol 143, pg 2096, 2018). *Analyst* 143, 3499-3499.

308 [21] Su, J.L., Beh, C., Ohmuro-Matsuyama, Y., Kitaguchi, T., Hoon, S. and Ueda, H. (2019).
309 Creation of stable and strictly regulated enzyme switch for signal-on immunodetection of various
310 small antigens. *Journal of Bioscience and Bioengineering* 128, 677-682.

311 [22] Zhu, B., Qian, C., Tang, H.X., Kitaguchi, T. and Ueda, H. (2023). Creating a Thermostable
312 beta-Glucuronidase Switch for Homogeneous Immunoassay by Disruption of Conserved Salt
313 Bridges at Diagonal Interfaces. *Biochemistry* 62, 309-317.

314 [23] Geddie, M.L. and Matsumura, I. (2007). Antibody-induced oligomerization and activation
315 of an engineered reporter enzyme. *J Mol Biol* 369, 1052-1059.

316 [24] Jansson, B., Uhlen, M. and Nygren, P.A. (1998). All individual domains of staphylococcal
317 protein A show Fab binding. *Fems Immunology and Medical Microbiology* 20, 69-78.

318 [25] Braisted, A.C. and Wells, J.A. (1996). Minimizing a binding domain from protein A. *Proc*
319 *Natl Acad Sci U S A* 93, 5688-5692.

320 [26] Scheffel, J., Kanje, S., Borin, J. and Hober, S. (2019). Optimization of a calcium-dependent
321 Protein A-derived domain for mild antibody purification. *MAbs* 11, 1492-1501.

- 322 [27] Ohmuro-Matsuyama, Y., Chung, C.I. and Ueda, H. (2013). Demonstration of protein-
323 fragment complementation assay using purified firefly luciferase fragments. *BMC Biotechnol* 13,
324 31.
- 325 [28] Asakura, T., Adachi, K. and Schwartz, E. (1978). Stabilizing Effect of Various Organic-
326 Solvents on Protein. *Journal of Biological Chemistry* 253, 6423-6425.
- 327 [29] Arakawa, T., Kita, Y. and Timasheff, S.N. (2007). Protein precipitation and denaturation
328 by dimethyl sulfoxide. *Biophys Chem* 131, 62-70.
- 329 [30] Lindman, S., Xue, W.F., Szczepankiewicz, O., Bauer, M.C., Nilsson, H. and Linse, S.
330 (2006). Salting the charged surface: pH and salt dependence of protein G B1 stability. *Biophys J*
331 90, 2911-2921.
- 332 [31] Pepys, M.B. and Hirschfield, G.M. (2003). C-reactive protein: a critical update. *J Clin*
333 *Invest* 111, 1805-1812.
- 334 [32] Jacobs, J.F., van der Molen, R.G., Bossuyt, X. and Damoiseaux, J. (2015). Antigen excess
335 in modern immunoassays: to anticipate on the unexpected. *Autoimmun Rev* 14, 160-167.
- 336 [33] Kell, D.B., Heyden, E.L. and Pretorius, E. (2020). The Biology of Lactoferrin, an Iron-
337 Binding Protein That Can Help Defend Against Viruses and Bacteria. *Front Immunol* 11, 1221.
- 338 [34] Ponzini, E., Scotti, L., Grandori, R., Tavazzi, S. and Zambon, A. (2020). Lactoferrin
339 Concentration in Human Tears and Ocular Diseases: A Meta-Analysis. *Invest Ophthalmol Vis Sci*
340 61, 9.
- 341 [35] Reseco, L., Atienza, M., Fernandez-Alvarez, M., Carro, E. and Cantero, J.L. (2021).
342 Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory
343 in aging. *Alzheimers Research & Therapy* 13, 150.

- 344 [36] Koshi, R., Kotani, K., Ohtsu, M., Yoshinuma, N. and Sugano, N. (2018). Application of
345 Lactoferrin and alpha1-Antitrypsin in Gingival Retention Fluid to Diagnosis of Periodontal
346 Disease. *Dis Markers* 2018, 4308291.
- 347 [37] Bagby, G.C., Jr. and Bennett, R.M. (1982). Feedback regulation of granulopoiesis:
348 polymerization of lactoferrin abrogates its ability to inhibit CSA production. *Blood* 60, 108-112.
- 349 [38] Levay, P.F. and Viljoen, M. (1995). Lactoferrin: a general review. *Haematologica* 80, 252-
350 267.
- 351 [39] Rosa, L., Cutone, A., Lepanto, M.S., Paesano, R. and Valenti, P. (2017). Lactoferrin: A
352 Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. *Int J Mol Sci* 18, 1985.